<--- Back to Details
First PageDocument Content
Medicine / Biology / Health / Nanomedicine / Biomedical engineering / Biocompatibility / Cancer stem cell / Liposome / Aptamer / Biomaterials / Esmaiel Jabbari / Targeted drug delivery
Date: 2015-10-23 04:21:11
Medicine
Biology
Health
Nanomedicine
Biomedical engineering
Biocompatibility
Cancer stem cell
Liposome
Aptamer
Biomaterials
Esmaiel Jabbari
Targeted drug delivery

ICoN2015 - Program 2nd International Conference on Nanotheranostics - ICoN2015 29 OctNov 2015 Limassol, Cyprus

Add to Reading List

Source URL: www.eng.ucy.ac.cy

Download Document from Source Website

File Size: 1,09 MB

Share Document on Facebook

Similar Documents

Laboratory Investigation, 970–982 & 2013 USCAP, Inc All rights reserved $32.00 PATHOBIOLOGY IN FOCUS  Patient-derived xenografts, the cancer stem cell

Laboratory Investigation, 970–982 & 2013 USCAP, Inc All rights reserved $32.00 PATHOBIOLOGY IN FOCUS Patient-derived xenografts, the cancer stem cell

DocID: 1uW4K - View Document

24th NSW Stem Cell Network Workshop Stem Cells and Cancer Darlington Centre City Rd, Sydney Wednesday, April 6th, 2016

24th NSW Stem Cell Network Workshop Stem Cells and Cancer Darlington Centre City Rd, Sydney Wednesday, April 6th, 2016

DocID: 1uNr2 - View Document

Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Car

Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Car

DocID: 1tWUj - View Document

A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

DocID: 1t7Mt - View Document

Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

DocID: 1t4Bh - View Document